BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1283 related articles for article (PubMed ID: 26529370)

  • 1. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
    Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Institution Propensity-Matched Study to Evaluate the Psychological Effect of Minimally Invasive Interval Debulking Surgery Versus Standard Laparotomic Treatment: From Body to Mind and Back.
    Gueli Alletti S; Vizzielli G; Lafuenti L; Costantini B; Fagotti A; Fedele C; Cianci S; Perrone E; Gallotta V; Rossitto C; Scambia G
    J Minim Invasive Gynecol; 2018; 25(5):816-822. PubMed ID: 29269126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
    Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
    J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study.
    Gueli Alletti S; Petrillo M; Vizzielli G; Bottoni C; Nardelli F; Costantini B; Quagliozzi L; Gallotta V; Scambia G; Fagotti A
    Gynecol Oncol; 2016 Dec; 143(3):516-520. PubMed ID: 27769526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy.
    Fagotti A; Gueli Alletti S; Corrado G; Cola E; Vizza E; Vieira M; Andrade CE; Tsunoda A; Favero G; Zapardiel I; Pasciuto T; Scambia G
    Int J Gynecol Cancer; 2019 Jan; 29(1):5-9. PubMed ID: 30640676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
    [No Abstract]   [Full Text] [Related]  

  • 8. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
    Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
    Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
    Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
    Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
    Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
    Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
    Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
    J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
    Corrado G; Mancini E; Cutillo G; Baiocco E; Vici P; Sergi D; Patrizi L; Saltari M; Baffa A; Vizza E
    Int J Gynecol Cancer; 2015 Sep; 25(7):1253-7. PubMed ID: 26111273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.
    Zhang Y; Grant MS; Zhang X; Paraghamian SE; Tan X; Clark LH
    J Minim Invasive Gynecol; 2021 Jun; 28(6):1237-1243. PubMed ID: 33248314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
    Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
    J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
    Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.
    Davidson BA; Broadwater G; Crim A; Boccacio R; Bixel K; Backes F; Previs RA; Salinaro J; Salani R; Moore K; Secord AA
    Gynecol Oncol; 2019 Mar; 152(3):554-559. PubMed ID: 30558972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer.
    Nakamura K; Kitahara Y; Nishimura T; Yamashita S; Kigure K; Ito I; Kanuma T
    World J Surg Oncol; 2020 Aug; 18(1):200. PubMed ID: 32791996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
    Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
    Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.